Background {#Sec1}
==========

Dystrophinopathies are the most common form of muscular dystrophy in childhood. They are caused by mutations in the *dystrophin* gene (*DMD*; OMIM \#300377) \[[@CR1], [@CR2]\]. Duchenne muscular dystrophy (DMD; OMIM \#310200) is a severe form of muscular dystrophy, with an incidence of 1 in 3600--5000 male births \[[@CR3]\]. Becker muscular dystrophy (BMD) is a milder form of DMD, with an incidence of 1 in 20,000 male births (BMD; OMIM \# 300376) \[[@CR4]\].

DMD is characterized by rapidly progressive degeneration and necrosis of the proximal muscles and calf pseudo-hypertrophy. Most *DMD* patients show muscle weakness at age 2 or 3, but it may be seen as early as infancy. Patients commonly lose independent ambulation by the age of 12 and die of dilated cardiomyopathy around the second or third decade. In comparison, patients with BMD exhibit relatively minor pathological symptoms, slower progression, later onset, and longer survival. Patients with an intermediate form of the disease, intermediate muscular dystrophy (IMD), may continue to walk until they are 16 years of age \[[@CR4], [@CR5]\].

The *DMD* gene is one of the largest known genes in humans, with 79 exons (approximately 2.4 Mb of genomic DNA) \[[@CR1]\] expressing a 427-kDa muscular protein that plays a fundamental role in stabilizing the sarcolemma. It does so by using a complex of glycoproteins associated with dystrophin to link actin filaments within the cytoskeleton and the extracellular matrix. Lack of dystrophin breaks these connections, altering the plasma membrane and finally producing myofiber degeneration and necrosis \[[@CR6]\]. Thus, according to the reading frame hypothesis \[[@CR7]\], *DMD* mutations that destroy the reading frame result in a truncated, non-functional dystrophin protein associated with a "DMD" phenotype. These mutations frequently generate a premature stop codon that activates nonsense-mediated mRNA decay \[[@CR8]\]. On the other hand, mutations that maintain the reading frame can permit semi-functional dystrophin protein and thus give rise to a "BMD" phenotype \[[@CR4], [@CR9]\]. Together, these two phenotype-genotype correlations explain more than 92% of all cases \[[@CR7]\].

Different types of mutations have been reported in patients with DMD and BMD. These are mainly large rearrangements (deletions in approximately 60--70% of patients and duplications in approximately 7--10%), with the remaining being point mutations (mainly nonsense mutations) and small deletions or insertions \[[@CR10], [@CR11]\]. Most gross deletions can be detected by multiplex PCR (mPCR) \[[@CR12], [@CR13]\] and are clustered in the proximal and central hot spot regions \[[@CR14], [@CR15]\]. Although a large proportion of the duplications were reported many years ago \[[@CR16], [@CR17]\], most laboratories do not systematically screen for these rearrangements. Duplication analysis and the determination of at-risk carrier status of the *DMD* gene require quantitative investigation, which is laborious and technically demanding \[[@CR18], [@CR19]\]. Previous studies have applied Southern blotting \[[@CR16], [@CR20]\], pulsed-field gel electrophoresis, quantitative mPCR \[[@CR21]--[@CR23]\], multiplex amplifiable probe hybridization \[[@CR24]\], and comparative genomic hybridization microarray \[[@CR25]\].

Given that deletions and duplications of one or more exons are found in the majority (70%) of patients, it is most cost-efficient and labor-efficient to check for these mutations first. A reliable and rapid technique, multiplex ligation-dependent probe amplification (MLPA), has been applied to cover the whole *DMD* gene to detect deletions and duplications and to identify exactly which exons are involved in deletions or duplications \[[@CR18], [@CR26]--[@CR29]\]. This approach reveals whether a given exon is present and allows the copy number of each exon to be calculated by comparing relative peak heights. MLPA can detect both deletions and duplications in patients as well as in female carriers. Compared to array comparative genomic hybridization, MLPA is a low-cost and technically uncomplicated method.

Although several studies have investigated exonic deletions in different populations \[[@CR11], [@CR30]--[@CR36]\], it is unknown where these deletions occur in the Saudi population. Although a few studies have described the molecular diagnosis of DMD in Saudi patients, the large deletions associated with disease were examined in only some exons, and the studies were limited by small sample sizes \[[@CR37], [@CR38]\]. Molecular characterization of the large *DMD* gene has been proposed to address large intragenic rearrangements in the whole exons of the *DMD* gene using an MLPA strategy covering nearly 75% of whole gene mutations. Thus, accurate molecular diagnosis may provide information on eligibility for mutation-specific treatments. A plausible frame shift hypothesis suggests how one might reduce disease severity via exon skipping, for example, by correcting the fidelity of the translational reading frame with large *DMD* deletions or restoring the wild type with large *DMD* duplications.

To our knowledge, the present study is the first study using the MLPA strategy to identify genotype-phenotype correlations in *DMD* patients in a Saudi community. Our results will add valuable data on de novo mutations in this population and to the databases of different DMD web pages as well.

Methods {#Sec2}
=======

Ethics statement and participants {#Sec3}
---------------------------------

All participants were enrolled under a protocol approved by the Institutional Biomedical Ethics Committee at Umm Al-Qura University (ref. \#HAPO-02-K-012). Parents of all participants gave written consent after being informed about the aim of the study.

The study included 45 unrelated male patients with DMD selected from 65 families from the western region of the Kingdom of Saudi Arabia (KSA), including Jeddah, Mecca, Taif, and Hada. Twenty additional eligible male patients did not enroll because their parents refused to share their clinical data, their clinical profiles were incomplete, or their creatine phosphokinase assessments were missing. For each patient included in the study, a clinical data sheet was recorded in the database of the Molecular Genetics Laboratory in the Department of Medical Genetics at Umm Al-Qura University. Clinical information was independent of any molecular DNA data for the *DMD* gene or its protein. *Dystrophin* probands were diagnosed by clinical geneticists or pediatricians based on strict criteria including a clinical presentation expected for DMD, family history of X-linked muscular dystrophy, or muscle biopsy with a dystrophin analysis performed using immunohistochemistry. Clinical diagnosis of dystrophin probands included age at onset, age at clinical evaluation, calf pseudohypertrophy, age at wheelchair confinement, cardiac function, and motor function. A histopathological study was performed before molecular DNA analysis if muscle biopsies were available. To avoid bias, we included only one case for each family. We categorized patients according to age at loss of ambulation: DMD ≤ 12 years, IMD 12--16 years, and BMD \> 16 years. Cases with a family history of autosomal recessive inheritance or with normal dystrophin protein were excluded.

DNA isolation {#Sec4}
-------------

Genomic DNA was isolated from buccal cells using the Oragene DNA-OGR-575 kit (DNA Genotek Inc., Ottawa, ON, Canada) according to the manufacturer's protocol with some modifications. Briefly, the full buccal cells were collected within 30 min, and the Oragene tube was capped immediately. The cells were incubated with the OGR-lysis buffer in a water bath at 53 °C to release the DNA, which was then precipitated by ethanol and dissolved in elution buffer \[[@CR39]\].

Multiplex polymerase chain reaction {#Sec5}
-----------------------------------

The genomic DNA of all *DMD* patients was subjected to multiplex PCR (mPCR) to screen for *DMD* deletions using 15 primer sets (Additional file [1](#MOESM1){ref-type="media"}: Table S1). The oligonucleotides included flanking sequences of exons 4, 8, 12, 17, 19, 44, 45, 48, and 51 \[[@CR12]\] and of exons 6, 13, 47, 50, 52, and 60 \[[@CR13]\]. We made some modifications to Chamberlain's mPCR set by not adding dimethylsulfoxide, which could result in a lower PCR yield. However, PCR cycling was programmed as initial denaturing at 95 °C for 6 min (1 round), then 94 °C for 30 s, annealing at 53 °C for 30 s, 65 °C for 4 min (repeated for 23 rounds), and final elongation at 65 °C for 7 min \[[@CR12]\]. Hot-start mPCR was performed using Beggs' PCR program \[[@CR13]\]: 95 °C for 6 min (1 round) and 25 subsequent cycles including DNA denaturing at 95 °C for 30 s, annealing at 56 °C for 1 min, and elongation at 68 °C for 4 min. Amplification reactions were carried out on thermal cycler Engine Dyad (Bio-Rad Laboratories Inc., Hercules, CA). PCR products (10--15 μl) were separated on 3% NuSieve agarose (BMA Bioproducts, Rockland, ME). The gels were viewed using the Gel Documentation and Analysis System (G-Box, SynGene, Frederick, MD, USA).

Multiplex ligation-dependent probe amplification {#Sec6}
------------------------------------------------

We analyzed all DMD cases for large deletions and large duplications using MLPA SALSA P034/P035 DMD kits (<http://www.mrc-holland.com>) following the manufacturer's instructions. In brief, denaturation, hybridization, ligation, and amplification steps were performed on a DNA Engine Dyad thermal cycler (Bio-Rad Laboratories Inc., Hercules, CA). Finally, PCR amplification was performed using SALSA MLPA PCR primers labeled with the FAM dye. A mixture of 0.7 μl of PCR product, 0.2 μl of 600 LIZ GS size-standard, and 9.0 μl of Hi-Di formamide was incubated for 3 min at 86 °C and cooled at 4 °C for 2 min. The MLPA product mix was separated on a POP7 polymer (Applied Biosystems Inc., Life Technologies, Foster City, CA) at 60 °C with the setting of 1.6 kV for injection voltage, 18 s for injection time, 15 kV for run voltage, and 1800 s for run time.

Data analysis {#Sec7}
-------------

The raw data were analyzed using GeneMapper Software 5 (Applied Biosystems Inc., Life Technologies, Foster City, CA). The DNA of cases with single-exon deletions were re-examined using conventional PCR. Initial analysis was performed with the naked eye to look for missed exon-specific peaks. For the remaining samples, the peak height of each exon was divided by the two nearest control peaks. The median ratio across all samples for each peak was calculated and used as a reference for one copy. For the sake of accuracy, any normalized ratio below 0.3 was considered a possible deletion. A duplication was considered if a normalized ratio was 1.8--2.0. If any single-exon deletion was identified, conventional PCR amplification was carried out to validate this deletion using primer sets and PCR conditions given in the Leiden Muscular Dystrophy pages (<http://www.dmd.nl>).

Databases and confirming mutations for the DMD gene {#Sec8}
---------------------------------------------------

We checked all mutations recorded in this study according to available databases established by the Leiden Muscular Dystrophy pages (<http://www.dmd.nl>) \[[@CR40]\], the Leiden Open Variation Database 3.0 ([http://www.lovd.nl/3.0/home](http://www.lovd.nl/3.0/new)) \[[@CR41]\], and UMD-DMD (<http://www.umd.be/DMD/>) \[[@CR31], [@CR32]\]. Databases for exon skipping to restore the DMD reading frame were found on sites developed by Leiden University Medical Center (<http://www.exonskipping.nl/?s=exon+skipping&submit=Go>) and CureDuchenne (<https://www.cureduchenne.org/cure/edystrophin/>).

### Statistical analysis {#Sec9}

Hardy-Weinberg equilibrium (HWE) deviation was examined for X-linked *DMD* cases in this study using the Online Encyclopedia for Genetic Epidemiology studies software (<http://www.oege.org/software/hwe-mr-calc.shtml>). We used the G\*Power Software (<http://www.psycho.uni-duesseldorf.de/abteilungen/aap/gpower3/download-and-register/>) to estimate power analysis to determine adequate sample sizes to achieve an 80% power for *t* testing of point biserial model. "*Priori*" sample size and "*post hoc*" power estimations were tested knowing our DMD sample size, a probability of *α* = 0.05, and the effect size index "*r*" (the absolute value of the correlation coefficient in the population, 0 \< "*r*" \< 1). We used paired *t* test analysis to compare the significant difference between the age at onset and the age of clinical evaluation for each *DMD* case. A two-sided *P* value less than 0.05 was considered to indicate statistical significance and 95% confidence interval (CI) for all analyses.

Results {#Sec10}
=======

Clinical profile {#Sec11}
----------------

Among 45 unrelated patients, 21 were diagnosed with DMD, 10 with IMD, and 5 with BMD. The unassigned patients were defined as not determined (ND), as they were too young to permit a definitive diagnosis (*n* = 9). The median age at onset was 3.5 years (range 1.0--7.0 years), while the median presenting age was 11.5 years (1.5--20 years) (Fig. [1](#Fig1){ref-type="fig"}). Most of the patients reported initial symptoms between 1 and 3 years of age (71.1%, 32/45), followed by those reporting symptoms at 4--5 years (24.4%, 11/45). The age at clinical evaluation was most frequently between 10 and 12 years (35.6%, 16/45). We found an extremely statistically significant difference between the age at initial symptoms and the age at clinical evaluation of DMD cases (*t* value, 10.3; 95% CI 5.95--8.8, *P* \< 0.0001). The mean difference in age between the two groups was 7.4 years.Fig. 1The age at onset and the age of clinical evaluation of DMD patients in this study. The analysis of DMD cases showed an apparent diagnostic delay

Hardy-Weinberg equilibrium {#Sec12}
--------------------------

All affected males were in HWE at the *DMD* gene deletions/duplications (*χ*^2^ = 1.00, *P =* 0.317), where the heterozygotes were absent in such X-linked recessive mode of inheritance.

Large-scale rearrangements {#Sec13}
--------------------------

Using mPCR, we identified 55 large deletions in the 45 unrelated *DMD* patients. MLPA detected 147 intragenic rearrangements, 68 (46.3%) of which were large deletions and 79 (53.7%) of which were large duplications. All deletions identified by mPCR were confirmed by the MLPA-based screening. The utility of MLPA assay for all exons is clear, as 13 (19%) of 68 deletions were detected using MLPA but were not detected by conventional mPCR analysis. The percentage of cases with deletions and duplications were 46.7% (21/45) and 17.8% (8/45), respectively. Table [1](#Tab1){ref-type="table"} includes the large rearrangements that were identified in the present study and had been previously described.Table 1Previously described large rearrangements identified in this study and their reading frame shiftsFamily no.PhenotypeMultiplex PCRMLPA del/dupExon(s) del/dupCodons del/dupFrame shiftAmino acid change^a^cDNA^a^DS-23DMDNo delDel 10--11371123 ^2/3^Stop at 323p.His321PhefsX3c.961_1331delDS-1DMDDel 19Del 18--20454151 ^1/3^− 1p.Arg723Lys874c.2169_2622delDS-37IMDDel 44Del 4414849 ^1/3^Stop at 2113p.Arg2098AsnfsX16c.6291_6438delDS-34NDDel 44--48Del 44--48808269 ^1/3^− 1p.Arg2098Gln2366delc.6291_7098delDS-24DMDDel 45Del 4517658 ^2/3^Stop at 2163p.Glu2147AlafsX17c.6439_6614delDS-8IMDDel 45--50Del 45--50871290 ^1/3^Stop at 2155p.Glu2147LeufsX9c.6439_7309delDS-38IMDDel 45--52Del 45--521222407 ^1/3^Stop at 2168p.Glu2147LeufsX22c.6439_7660delDS-29DMDDel 47--50Del 47--50547182 ^1/3^Stop at 2263p.Val2257LeufsX7c.6763_7309delDS-20NDDel 47--50Del 47--50547182 ^1/3^Stop at 2263p.Val2257LeufsX7c.6763_7309delDS-48BMDDel 48Del 4818662*In-frame*p.Val2305Gln2366delc.6913_7098delDS-30DMDDel 50Del 49--5021170 ^1/3^Stop at 2375p.Glu2367LeufsX9c.7099_7309delDS-31IMDDel 50Del 49--5021170 ^1/3^Stop at 2375p.Glu2367LeufsX9c.7099_7309delDS-36DMDDel 50Del 5010936 ^1/3^Stop at 2409p.Arg2401LeufsX9c.7201_7309delDS-32IMDDel 50Del 5010936 ^1/3^Stop at 2409p.Arg2401LeufsX9c.7201_7309delDS-33NDDel 50Del 5010936 ^1/3^Stop at 2409p.Arg2401LeufsX9c.7201_7309delDS-35NDDel 50Del 5010936 ^1/3^Stop at 2409p.Arg2401LeufsX9c.7201_7309delDS-27NDDel 50--52Del 50--52460153 ^1/3^Stop at 2422p.Arg2401LeufsX22c.7201_7660delDS-12DMDDel 51Del 5123377 ^2/3^Stop at 2469p.Ser2437CysfsX33c.7310_7542delDS-18DMDNo delDel 5519063 ^1/3^Stop at 2700p.Val2677ThrfsX24c.8028_8217delDS-11NDNo delDup 50--51343114*In-frame*p.Arg2401Lys2514dupc.7201-?\_7542 +?dup*DMD* Duchenne muscular dystrophy, *IMD* intermediate muscular dystrophy, *BMD* Becker muscular dystrophy, *ND* not determined^a^These data are based on the Leiden Muscular Dystrophy Pages (<http://www.dmd.nl/>) and the UMD-DMD (<http://www.umd.be/DMD/>)

New mutations in the *DMD* gene {#Sec14}
-------------------------------

We also identified seven previously undescribed large *DMD* rearrangements from eight Saudi cases. These new mutations, based on the *DMD* databases \[[@CR31], [@CR32], [@CR40], [@CR41]\], included one mixed rearrangement (del 45--52 + dup 21--23), one large deletion (del 45--56), two large duplications (8--30 and 17--24), and three double duplications (dup 2--4 + dup 18--19, dup 13 + dup 21--24, and dup 56--58 + dup 62--64). These large mutations were from eight (17.8%) of the Saudi patients (Table [2](#Tab2){ref-type="table"}).Table 2New *DMD* mutational rearrangements identified in this study and their predicted reading frame shiftsCase no.PhenotypeMultiplex PCRMLPA del/dupExon(s) del/dupCodons del/dupFrame shiftAmino acid change^a^DS-2DMDNo deldup 2--4 and dup 18--19233;\
21277 ^2/3^\
70 ^2/3^+ 2\
+ 2p.Val89MetfsX15 ^b^\
p.Lys724Gly795fsX1DS-14DMDNo deldup 8--3036791226 ^1/3^+ 1p.Val218K1412fsXDS-15NDNo deldup 8--3036791226 ^1/3^+ 1p.Val218K1412fsXDS-52BMDNo deldup 13 and dup 21--24120\
65440\
2180\
0p.Val495Val535dup\
p.Asp875Lys1093dupDS-50BMDNo deldup 17--2412484280p.Ile665Lys1093dupDS-53IMDdel 45--51del 45--52 and dup 21--231222;\
540407 ^1/3^\
180− 1^c^\
0p.Glu2147LeufsX22 ^C^\
p.Asp875Asn1055dupDS-25IMDdel 45--51del 45--561952650 ^2/3^− 2p.Glu2147Ser2798DS-22DMDNo deldup 56--58 and dup 62--64451\
198150 ^1/3^\
66+ 1\
0p.Ser2798Lys2891fsX4\
p.Ser3056Asp3122*DMD* Duchenne muscular dystrophy, *IMD* intermediate muscular dystrophy, *BMD* Becker muscular dystrophy, *ND* not determined^a^Theoretical amino acid change based on the database of the Leiden Muscular Dystrophy Pages (<http://www.dmd.nl/>)^b^Previously described duplication at cDNA (c.6439_7660del) showing amino acid change (p.Glu2147LeufsX22) resulting in a termination transcript at codon 2168^c^Previously described deletion at cDNA (c.32_265dup) showing amino acid change (p.Val89MetfsX15) resulting in a termination transcript at codon 103

Distribution of rearrangements {#Sec15}
------------------------------

In this study, deletions did not have a random distribution. We found that 92.5% (63/68) of hot spot deletions were linked to exons 44--56 (central region), whereas 7.5% (5/68) of deletions were related to exons 10--20. Exon 50 was most frequently involved in deletions (19.1%, 13/68), followed by exons 48 and 49 (each 11.8%, 8/68). The rate of deletions increased from a minimum in exon 44 to a maximum in exon 50 and then decreased until the 3′ end of the *DMD* gene, with no deletion in exons 57--79 (distal region) (Fig. [2](#Fig2){ref-type="fig"}). Moreover, we found that the number of cases with a deletion of *only* one exon was lower than the number with deletions of more than one exon (9/21, 42.8% versus 12/21, 57.1%). About half of the deletions (44.4%) were detected only once, in agreement with the high allelic heterogeneity of the *DMD* gene.Fig. 2The frequency of large mutational rearrangements for each exon of the *DMD* gene. A region with a high frequency of deletions was found in exons 44--56. No such region of frequency was detected for large duplications

Duplications were distributed in the proximal (68/79, 86.1%), central (5/79, 6.3%), and distal regions (6/79, 7.6%) (Fig. [2](#Fig2){ref-type="fig"}). Unlike deletions, duplicated exons were more frequent in the proximal region (26 duplications) than in the central and distal regions (13 duplications). The most frequent duplications were of exons 21, 22, and 23 (7.6%, 6/79 each), followed by exons 18 and 19 (5.1%, 4/79 each). We did not find any duplications in exons 31--49 (central region) or exons 69--79 (distal region) within our cases (Fig. [2](#Fig2){ref-type="fig"}). Similar to deletions, 42.5% of exonic duplications (17/40) were observed only once, revealing a considerable heterogeneity of duplications.

Reading frame shift and phenotype correlation {#Sec16}
---------------------------------------------

Gene rearrangements (deletions and duplications) were correlated with clinical phenotypes in 28 unrelated cases: 11 (39.3%) with DMD, 7 (25%) with IMD, 3 (10.7%) with BMD, and 7 (25%) with ND. We also predicted the translational reading frame in 28 DMD cases with rearrangements identified in this study, using the Leiden Muscular Dystrophy pages (<http://www.dmd.nl>). Applying the reading frame rule revealed consistency with the frame shift rule for 90.9% (10/11) of the individuals with DMD phenotypes and 100% (7/7) of the individuals with IMD phenotypes. Likewise, the *DMD* genes in all cases with BMD phenotypes had in-frame functional effects on the DMD protein (cases \#DS-48, \#DS-50, and \#DS-52) (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}). All previously described rearrangements we detected gave rise to a stop codon and thus a truncated protein, except for case \#DS-48 with a BMD phenotype and case \#DS-11 with ND, which gave rise to in-frame predictions (Table [2](#Tab2){ref-type="table"}). Two cases identified in this study (\#DS-53 and \#DS-22) reflected both in-frame and reading frame shift predictions (Fig. [3](#Fig3){ref-type="fig"}). The complex rearrangement of case \#DS-53 (del 45--52 + dup 21--23) was associated with an IMD phenotype, with translational reading frame predictions with in-frame and frame shift patterns (Fig. [3](#Fig3){ref-type="fig"}). This phenotype may have occurred from the addition of exons 21--23 to the mRNA transcript lessening the damaging effect of del 45--52 on the functional protein. On the contrary, case \#DS-22 could not have corrected for the harmful dup 56--58, giving rise to a DMD phenotype (Table [2](#Tab2){ref-type="table"}).Fig. 3A schematic overview of new complex large rearrangements in the *DMD* gene. **a** The case \#DS-53 with an unusual mixed rearrangement (dup 21--23 + del 45--52) leads to an out-of-frame shift giving rise to a severe DMD phenotype. **b** The case \#DS2 with a double duplication (dup 2--4 + dup 18--19) results in out-of-frame shifts with a DMD phenotype. **c** The case \#DS-52 with two *in-frame* shift due to double duplications (dup 13 + dup 21--24) giving rise to a BMD phenotype. **d** The case \#DS-22 showed two double duplications within the mature mRNA giving an out-frame (dup 56--58), in-frame (dup 62--64) mutations giving rise to a DMD phenotype

Discussion {#Sec17}
==========

The present study used a facile, reliable, and time-consuming MLPA strategy to identify large rearrangements covering all 79 exons of the *DMD* gene. Our results showed the prevalence of 46.7 and 17.8%, respectively, for large deletions and large duplications in 45 Saudi patients with DMD. Unlike the hot spot deletions in exons 44--56 (92.5%), the hot spot deletions near the 5′ end of the gene were not distinctive, and no large hot spot duplications were found anywhere along the *DMD* gene. The presence of an unusual MLPA pattern in our Saudi sample, including non-contiguous duplications as well as contiguous deletions combined with non-contiguous duplications, suggests complex rearrangements. Our findings regarding double, separate duplications and complex rearrangements are consistent with some previous reports in Serbian and South African patients \[[@CR18], [@CR42]\].

Results from MLPA-related studies among different ethnic populations are conflicting in terms of rates of large rearrangements within the *DMD* gene. Studies have found rates of deletions (and duplications) of 71.8--79.0% (16.4--19.8%) in Chinese \[[@CR29]\], 79.5% (6.5%) in Indian \[[@CR43]\], 60% (10.0%) in Japanese \[[@CR44]\], 45.5--71.8% (16.7%) in Korean \[[@CR35]\], and 28.2% (20.5%) in Taiwanese \[[@CR45]\] populations. When compared with our sample, a Turkish sample has also been shown to have a relatively higher rate of deletions within the *DMD* gene (63.7%) \[[@CR46]\], likely because of admixture with other European ethnicities. Rates of *DMD* deletions and duplications in some other Middle Eastern populations are more similar to what we found: Egyptian (51.3% deletions) \[[@CR47]\], Iranian (51% deletions) \[[@CR48]\], Moroccan (51% deletions) \[[@CR49]\], and Syrian (49.0% deletions; 9.8% duplications) \[[@CR50]\]. The majority of the reported *DMD* gene mutations in our Saudi data showed translational reading frame shifts (94.4%), while 5.6% of the mutations did not follow the reading frame rule. This latter outcome is relatively consistent with the corresponding values in the TREAT-NMD DMD Global database (7%) \[[@CR11]\], the UMD-DMD database (4%) \[[@CR32]\], and the Leiden database (9%) \[[@CR41]\].

The overall rate of consanguinity in KSA is 57.7%, ranging from 34 to 80.6% \[[@CR51]\], with lower rates in Mecca (North Western region) than in Riyadh (Central region) (44.1% versus 62.8%) \[[@CR51]\]. This may account for the increased deletions in patients of Riyadh (21/27, 77.8%) when compared with those in our study \[[@CR37]\]. During Muslim immigration from the Levant, Africa, in Ancient Islamic times, much intermarriage reinforced gene flow of the *DMD* gene to the Saudi people. This has likely influenced the prevalence of different Mendelian patterns, particularly X-linked types, exemplified by the consistency of data for *DMD* rearrangements between our study and a recent Spanish cohort study (46.1%, 131/284 for deletions and 56/284, 19.7% for duplications) \[[@CR52]\].

It is noteworthy that some populations have inherent reproductive barriers that prevent interbreeding, which keeps them at native levels without merging (i.e., cryptic taxa). Other populations may lack inherent reproductive isolation. Therefore, admixture among different geographical populations might increase genetic variations and perhaps create new genotypic combinations within non-isolated (or non-native) populations \[[@CR53]\]. Thus, genetic variations among Gulf Arabs and some Middle Eastern individuals (e.g., Barbarians in North Africa, Kurdish, Upper Egyptian) \[[@CR54], [@CR55]\] should be handled with caution, as increased consanguinity, extensive reproductive isolation, and admixture with native source populations (e.g., Black Africans, South Eastern Asians, Caucasians) have had substantial roles in gene flow or founder effects in these populations.

In our study, the analysis of *DMD* cases showed an apparent diagnostic delay, as 69.8% of our patients showed their first symptoms at an early age (1--3 years), but 44% of these patients were 9--12 years old at first clinical examination. Other countries have also reported long delays in diagnosis of the disease, with a mean delay between 1.6 and 2.5 years \[[@CR56], [@CR57]\]. In south China, the first symptoms occurred by 3 years of age, but the age at clinical evaluation was 6--8 years \[[@CR36]\]. Numerous studies have advocated raising public awareness to identify early symptoms in DMD patients \[[@CR47], [@CR57], [@CR58]\], as parents are usually the first to notice symptoms, which prompt them to visit a health professional. To further reduce diagnostic delay, creatine phosphokinase (CPK) testing should be emphasized in primary care and performed as a routine test in children's physical examinations.

Earlier clinical trials reported the safety and biochemical efficacy of intravenous or intramuscular administration of antisense oligonucleotides (20-30 mer) to bring hope to DMD patients with large deletions \[[@CR59]\]. Therefore, inducing exon 51 skipping to restore the open reading frame is an attractive therapeutic strategy that can be achieved with splice-switching oligomers. After the US Food and Drug Administration (FDA) accelerated approval of AVI-4658/eteplirsen (Exondys 51; Sarepta Therapeutics Inc., Cambridge, MA, USA), targeting *DMD* exon 51 skipping, *eteplirsen* was approved and introduced in some countries \[[@CR60]--[@CR63]\]. Eteplirsen is useful for patients with amenable *DMD* deletions, ending at exon 50 and starting at exon 52 \[[@CR64]\]. To date, eteplirsen has not been approved by the Saudi FDA (<https://www.sfda.gov.sa>). Hence, numerous efforts have used antisense oligomers to target exon skipping of exon 53 (SRP4053, PRO053), exon 45 (DS-514b, SRP4045), and exon 44 (PRO044) (<https://www.clinicaltrials.gov/beta/home>) \[[@CR62], [@CR65]\]. Based on our data for deletions, exon skipping could eventually apply to 81% (17/21) of DMD cases with large deletions. Among our Saudi patients with *DMD* gene deletions, the exons most frequently skipped were exons 51 (42.9%, 9/21), 53 (14.3%, 3/21), 44 (9.5%, 2/21), 45 (4.8%, 1/21), 43 (4.8%, 1/21), and 50 (4.8%, 1/21). Wein et al. have recently reported the efficiency of exon skipping in the *DMD* gene, with each duplicated exon expressing a wild-type, full-length mRNA \[[@CR66]\]. For more than one duplicated exon, several antisense oligomers can be delivered as a cocktail of drugs to skip larger regions of the transcript. Thus, for duplications in exons 45--55, therapeutic skipping can be applied to more than 60% of all DMD patients \[[@CR67]\].

Although the power is conventionally utilized for polygenic disorders, the power under different monogenic model of inheritance has not been systematically considered. This issue could be explained because of wide issues, for example, rate of background variation in disease-associated genes, mode of inheritance, extent of penetrance, and locus heterogeneity.

In contrast to dominant model of inheritance, the incomplete penetrance does not hold for the recessive model, and in consequence, much smaller sample sizes are needed under a recessive model, even in the presence of high locus heterogeneity \[[@CR68]\]. According to our *priori* sample size estimations at the effect size "*r*" = 0.3 (medium effect), or "*r*" = 0.5 (strong effect), we would need 64 or 21 sample sizes, respectively, to ensure a power detection of 80%. Thus, post hoc analysis using our DMD sample size data in this study (*n* = 45 cases) could achieve the power of 66.7% (*r* = 0.3) and 98.5% (*r* = 0.5).

Pinning down the spectrum of mutations for *DMD* has been difficult because of poor replication of studies. First, when compared with our study, some studies have had populations with admixed ethnicities, conflicted outcomes, or small sample sizes, which lessen the strength of the overall results. Second, various molecular technologies have been utilized to examine *DMD* patients, resulting in a broad range of false-positive or false-negative results regarding rearrangements. Our study mainly used the *DMD* MLPA test, providing a cheap and straightforward DNA-based test that can screen for deletions and duplications and be performed in any DNA laboratory. Third, insufficient communication between clinicians and geneticists, because of difficulty accessing hospitals of interest, may result in underdiagnosis of critical cases. However, precise coordination between clinicians and geneticists may help promote and improve the genetic diagnosis of dystrophinopathies and ameliorate potential therapies in these cases.

Conclusions {#Sec18}
===========

We detected nine previously undescribed exonic rearrangements within the *DMD* gene, including one unusual mixed rearrangement. MLPA or mPCR can be used to define the molecular characteristics of *DMD* rearrangements and hence the effects of the frame shifts on genotype-phenotype correlations in Saudi patients. This information will also be important for future gene therapy targeting exon skipping of the *DMD* gene. Our clinical characteristics revealed a diagnostic delay, suggesting the need for more public awareness about early symptoms of disease. However, CPK testing should also be performed as a routine test in children's hospitals and in primary care settings. In KSA, molecular testing of DMD patients should be covered by medical insurance, at least once in a lifetime. This single test could lead to genetic diagnosis of more patients. The large deletions and duplications we identified are predictive and intriguing, but the study needs to be replicated in different ethnic populations of the Middle East, as well as in other Saudi governorates. Though the sample size for this study might not have been large enough to explore the *DMD* mutational mechanisms, extensive sequencing analyses will be needed to discover the *DMD* breakpoints at the nucleotide level. Ongoing analyses of whole-exome sequences for Saudi patients with DMD are being carried out to identify the small breakpoints within the *DMD* gene.
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Additional file 1:**Table S1.** Oligonucleotide Sequences of 15 multiplex PCR sets and amplification size fragments. (DOCX 17 kb)

BMD

:   Becker muscular dystrophy

CPK

:   Creatine phosphokinase

DMD

:   Duchenne muscular dystrophy

FDA

:   Food and Drug Administration

IMD

:   Intermediate muscular dystrophy

KSA

:   Kingdom of Saudi Arabia

MLPA

:   Multiplex ligation-probe dependent amplification

ND

:   Not determined
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